Reiner Laus

Dendreon Corp. discovers, develops and commercializes novel products for the treatment of cancer. The company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy ACI product candidates designed to stimulate an immune response in a variety of tumor types. It is an exploring the application of additional ACI product candidates and small molecules for the potential treatment of a variety of cancers. Dendreon was founded by Christopher S. Henney, Edgar G. Engleman and Samuel Strober in 1992 and is headquartered in Seattle, WA.

Bavarian Nordic, Inc. engages in researching and manufacturing drugs to treat cancer. The company is headquartered in Morrisville, NC.

Annias Immunotherapeutics, Inc. operates as an clinical stage company. It develops and sells therapeutic vaccine for the treatment of malignant brain tumor. The company is headquartered in Saratoga, CA.

TRIO Pharmaceuticals, Inc. is a privately held cancer therapeutics company based in QB3. Triobody™ and TDC™ can synergize with current cancer drugs to improve efficacy. The American company is pioneering dual action drugs to generate immunogenic tumors. The company's innovative antibody drugs directly stop tumor growth and selectively stop immunosuppression in the tumor without targeting the current immune checkpoint pathways. The company was founded by Reiner Laus and is developing first-in-class dual action antibody drug conjugates, Triobody Drug Conjugate (TDC™), and dual action antibody drugs, Triobody™, that stop both tumor growth and immunosuppression with and without payload delivery, respectively.